An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug resistant epilepsy in the United States.
Christopher RaspinR Edward FaughtJeanne ArmandFrancesca BarionVicki PollitJoanna MurphyVanessa DanielsonPublished in: Journal of medical economics (2023)
VNS was evaluated as a cost-effective addition to the current standard of care in the treatment of DRE in the US Medicare context.